While vaccine makers insist any COVID-19 vaccine reaching the market will have undergone rigorous testing, the way trial protocols are designed suggests these vaccines will not have a significant impact on infection rates, hospitalizations or deaths. Shockingly, preventing infection with SARS-CoV-2 is not a criterion for success in these vaccine trials. The only criterion for a successful COVID-19 vaccine is a reduction of symptoms shared by both COVID-19 and the common cold. https://articles.mercola.com/sites/articles/archive/2020/10/27/covid-vaccine-trials.aspx